Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Phillips 66 — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B), while Phillips 66 trades at $281 (market cap $108.38B). The key difference: Phillips 66 is far larger — about 63.4× Nuvation Bio Inc. Class A Common Stock's market cap, and Phillips 66 pays a 1.87% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Phillips 66 for 62 Days on average.
| NUVB | PSX | |
|---|---|---|
Market Cap | $1.71B | $108.38B |
Volume | 5,448,712 | 1,841,742 |
Sector | Health | Energy |
52-Week High | $9.54 | $281.60 |
52-Week Low | $3.41 | $126.76 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $1.30B | $124.85B |
Dividend Yield | — | 1.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PSX trades at $281.60, up 4.38% today, near its 52-week high. The stock shows bullish technical momentum with strong moving average support. Fundamentally, the company has beaten earnings estimates for three consecutive quarters, with a P/E of 15.5 and robust ROE of 24.02%. Recent news highlights structural strength in refining margins and AI-driven operational improvements.
Outlook remains positive with analyst consensus at Buy (57% of ratings) and a $279 price target. Key opportunities include sustained refining profitability and debt reduction. Risks involve volatile energy markets and potential policy impacts on diesel exports. Cash flow is projected to rebound to $3.0B in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
